Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe